Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21788630 | 1.00 | KDM1A (0.73) | KDM1A | |
| SCHEMBL21784461 | 1.00 | KDM1A (0.73) | KDM1A | |
| SCHEMBL21784346 | 1.00 | KDM1A (0.73) | KDM1A | |
| SCHEMBL21775421 | 0.88 | KDM1A (0.57) | KDM1A | |
| SCHEMBL16989443 | 0.85 | KDM1A (0.83) | KDM1A | |
| SCHEMBL16989441 | 0.85 | KDM1A (0.83) | KDM1A | |
| SCHEMBL16995855 | 0.85 | KDM1A (0.83) | KDM1A | |
| SCHEMBL22922935 | 0.85 | KDM1A (1.00) | KDM1A | |
| SCHEMBL16989535 | 0.85 | KDM1A (1.00) | KDM1A | |
| SCHEMBL16995789 | 0.85 | KDM1A (1.00) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300891-A1 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME | INCYTE CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-10968200-B2 | Salts of an LSD1 inhibitor and processes for preparing the same | INCYTE CORPORATION (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2020047198-A1 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME | INCYTE CORPORATION (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300891-A1 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME | KDM1A, KDM1B, KDM2A | KDM1A 1/4885 |
| US-10968200-B2 | Salts of an LSD1 inhibitor and processes for preparing the same | KDM1A, KDM1B, KDM2A | KDM1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.